Bonus Biogroup (BONS), a late-stage biotechnology company, on Thursday announced that it has received U.S. FDA clearance for its Investigational New Drug or IND application to proceed with a Phase III clinical study of MesenCure.
This study will evaluate the efficacy and safety of MesenCure, an enhanced allogeneic cell therapy consisting of adipose tissue-derived mesenchymal stromal cells or MSC, in treating respiratory distress in severely ill patients, particularly those suffering from pneumonia related to COVID-19.
Bonus Biogroup is working to expand the study to include acute respiratory distress syndrome or ARDS, with findings from Phase II clinical trials showing promising results such as a 68 percent reduction in 30-day all-cause mortality and a 57 percent decrease in invasive ventilation needs among treated patients.
The company estimates MesenCure's market potential in treating all-cause ARDS in the U.S. could reach $9.6 billion by 2030.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.